Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson–Gilford progeria syndrome mutation
- 26 November 2007
- journal article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1781 (1-2) , 36-39
- https://doi.org/10.1016/j.bbalip.2007.11.003
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Mislocalization of prelamin A Tyr646Phe mutant to the nuclear pore complex in human embryonic kidney 293 cellsBiochemical and Biophysical Research Communications, 2007
- Alterations in mitosis and cell cycle progression caused by a mutant lamin A known to accelerate human agingProceedings of the National Academy of Sciences, 2007
- Protein farnesyltransferase inhibitors and progeriaTrends in Molecular Medicine, 2006
- A Protein Farnesyltransferase Inhibitor Ameliorates Disease in a Mouse Model of ProgeriaScience, 2006
- Prelamin A and lamin A appear to be dispensable in the nuclear laminaJournal of Clinical Investigation, 2006
- Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft ModelsClinical Cancer Research, 2005
- Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndromeNature Medicine, 2005
- Lamin A Truncation in Hutchinson-Gilford ProgeriaScience, 2003
- Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndromeNature, 2003
- The Hutchinson-Gilford progeria syndromeThe Journal of Pediatrics, 1972